[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 18, 1995

PEPI in PerspectiveGood Answers Spawn Pressing Questions

Author Affiliations

From the Page Center for Health and Science Policy Studies, the Cleveland Clinic Foundation, Cleveland, Ohio.

JAMA. 1995;273(3):240-241. doi:10.1001/jama.1995.03520270074035
Abstract

Estrogen is good for a woman's heart. While generally accepted when the estrogen is produced naturally, this theory has been a matter of great controversy when the estrogen is administered "artificially" in hormone replacement therapy (HRT) for women during and after menopause. After a half century of conflicting data, we can affirm with growing confidence that, at the very least, estrogen reduces key cardiovascular risk factors in women at a time when they become especially vulnerable to heart disease, namely, after 50 years of age.

See also p 199.

In this issue of The Journal, the Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators report on one aspect of the many findings that we can expect to learn over the next few years from their important National Institutes of Health (NIH)-supported multicenter efforts.1 Their report focuses on the effect of HRT, given in four different formulations, compared with short-term use of placebo

First Page Preview View Large
First page PDF preview
First page PDF preview
×